Health × Macro
FDA clears Eli Lilly's Foundayo—first oral GLP-1
On April 1, FDA approved Eli Lilly's once-daily oral GLP-1 Foundayo (orforglipron) for obesity and overweight. The ATTAIN-1 trial posted 12.4% average weight loss (27.3 pounds) at the highest dose. LillyDirect ships April 6 at $149/month out-of-pocket.
Primary sources · 3